BROADCASTS.com

Swim through the sea of acronyms as Dr Scott Matherly (@liverprof) helps us become a little less baffled by the thought of NAFLD. We discuss the initial diagnosis of fatty liver disease, indications for additional evaluation with imaging and/or biopsy, and potential treatment options. With a quarter of the world affected, it\u2019s crucial to understand the various forms of disease and how to counsel patients about this all-too-common condition!

Show Notes | Subscribe | Spotify | Swag! | Top Picks | Mailing List | thecurbsiders@gmail.com | Free CME!

\n
• Written and Produced by: Elena Gibson MD
  \n\n
\n
• Infographic and Cover Art: Elena Gibson MD
  \n\n
\n
• Hosts: Matthew Watto MD, FACP; Paul Williams MD, FACP
  \n\n
\n
• Editor: Emi Okamoto MD (written materials); Clair Morgan of nodderly.com
  \n\n\n
\n
• Guest: Scott Matherly MD
  \n\n
\n

Sponsor: Pediatrics On Call

\n

Sponsor: \xa0VCU Health Continuing Education to offer continuing education credits for physicians and other healthcare professionals. Check out curbsiders.vcuhealth.org and create your FREE account!

\n
• \n00:00 Intro
  \n\n
\n
• \n03:15 Guest one-liner; Picks of the Week*\u2028:
  \n\n\n
\n
• \n08:15 Sponsor
\n
• \n08:50 Case from Kashlak part 1; What is hepatic steatosis?
  \n\n
\n
• \n11:43 NAFLD acronyms and definitions
  \n\n
\n
• \n18:20 Alcohol and Fatty Liver
  \n\n
\n
• \n23:15 Initial Evaluation of NAFLD
  \n\n
\n
• \n35:12 Dr Matherly\u2019s piel to patients with fatty
  \n\n
\n
• \n41:11 NASH/Fibrosis Risk Assessment
  \n\n
\n
• \n48:54 Outcomes in NASH with Fibrosis
  \n\n
\n
• \n51:20 Statins are safe in liver disease
  \n\n
\n
• \n56:15 Treatment Options (surgery, Vitamin E, Pioglitazone, SLGT2 inhibitors and GLP1 agonists; Coffee?!)
\n
• \n71:42 Take home points and Outro
\n